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Abstract
Background: Given the complex and progressive nature of Alzheimer’s disease (AD), a precision medicine approach
for diagnosis and treatment requires the identification of patient subgroups with biomedically distinct and actionable
phenotype definitions.
Methods: Longitudinal patient-level data for 1160 AD patients receiving placebo or no treatment with a follow-up of
up to 18 months were extracted from an integrated clinical trials dataset. We used latent class mixed modelling (LCMM)
to identify patient subgroups demonstrating distinct patterns of change over time in disease severity, as measured by the
Alzheimer’s Disease Assessment Scale—cognitive subscale score. The optimal number of subgroups (classes) was selected
by the model which had the lowest Bayesian Information Criterion. Other patient-level variables were used to define
these subgroups’ distinguishing characteristics and to investigate the interactions between patient characteristics and
patterns of disease progression.
Results: The LCMM resulted in three distinct subgroups of patients, with 10.3% in Class 1, 76.5% in Class 2 and 13.2% in
Class 3. While all classes demonstrated some degree of cognitive decline, each demonstrated a different pattern of
change in cognitive scores, potentially reflecting different subtypes of AD patients. Class 1 represents rapid decliners
with a steep decline in cognition over time, and who tended to be younger and better educated. Class 2 represents
slow decliners, while Class 3 represents severely impaired slow decliners: patients with a similar rate of decline to Class
2 but with worse baseline cognitive scores. Class 2 demonstrated a significantly higher proportion of patients with a
history of statins use; Class 3 showed lower levels of blood monocytes and serum calcium, and higher blood
glucose levels.
Conclusions: Our results, ‘learned’ from clinical data, indicate the existence of at least three subgroups of Alzheimer’s
patients, each demonstrating a different trajectory of disease progression. This hypothesis-generating approach has
detected distinct AD subgroups that may prove to be discrete endophenotypes linked to specific aetiologies. These
findings could enable stratification within a clinical trial or study context, which may help identify new targets for
intervention and guide better care.
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Background
Despite substantial investments in research to find better
Alzheimer’s disease (AD) therapies, most drug develop-
ment efforts end in failure [1–3]; to date, there are no
generally effective therapies for AD [1]. Part of the rea-
son for widespread failure of therapeutic development
for Alzheimer’s may be due to treating all persons with
the disease as if they were the same. One potential route
to achieving successful and timely identification of ef-
fective therapies is to identify subgroups of patients who
may be more responsive to existing and experimental in-
terventions. Given the complexity and progressive na-
ture of AD, there are likely to be distinctive phenotypes
and genotypes that respond to candidate therapies differ-
ently, and therefore a precision approach to prevention
and treatment is critical. Such an approach, where per-
sons with the disease are considered based on an endo-
type, could identify therapeutics that could delay
progression of disease to gain the 5-year window neces-
sary to reduce incidence of the disease.
By employing a data-driven, statistical learning ap-
proach, we investigated whether distinct subgroups of
AD were apparent in an integrated clinical trial dataset;
and whether these subgroups were associated with spe-
cific clinical features or existing therapies that might
have delayed AD progression. Here, we report that clin-
ically meaningful subgroups can be identified and these
might be used to stratify patient populations for better
AD management and care.
Methods
Study participants and data
Data were derived from an integrated dataset of AD clin-
ical trials and observational studies described previously
[4, 5]. The datasets consisted of 18 studies from the Alz-
heimer’s Disease Cooperative Study (ADCS, http://
adcs.org) and the Alzheimer’s Disease Neuroimaging Ini-
tiative (ADNI, http://www.adni-info.org) conducted from
1993 to 2012 to analyse the decline in sores on the Alzhei-
mer’s Disease Assessment Scale—cognitive subscale [6]
(ADAS-cog), Clinical Dementia Rating—Sum of Boxes [7]
(CDR-SB) scale and Mini-Mental State Examination [8]
(MMSE) over time. The integrated dataset includes
demographics information, cognitive assessments, Apoli-
poprotein E (ApoE) genotyping, concomitant medication
information and blood test data for a total of 4574 partici-
pants and 25,164 encounters. All diagnoses of AD were
based on National Institute of Neurological and Commu-
nicative Disorders and Stroke/Alzheimer’s Disease and Re-
lated Disorders Association criteria [9]. Routine use of
different medications was captured from the concomitant
medication logs using brand and generic names as the
search terms. In this study we examined the use of statins,
non-statin cholesterol-lowering drugs, AD medications,
antidepressants, non-steroid anti-inflammatory drugs
(NSAIDs), oestrogens, diabetes medications, vitamin
E, omega-3 and derivatives, and medications for long-
term asthma management. Medication use was evalu-
ated at the baseline visit of the study into which
participants were recruited. A full list of drug groups
and search terms is presented in Additional file 1; po-
tential misspelling of drug names was not accounted
for. From this dataset we selected those participants
with a diagnosis of AD who were treated with pla-
cebo or not treated at all, resulting in data from 1160
participants. Of these, 16% of participants originated
from the ADNI study while the remaining 84% origi-
nated from ADCS studies.
Latent class analysis
We used latent class mixed modelling (LCMM) with the
aim of identifying subgroups of patients with statistically
distinct changes in cognitive scores over time, as mea-
sured by the ADAS-cog. The observation period for
each participant started at beginning of the study they
were recruited into and continued for up to 18 months
(with a mean ± SD follow-up of 12.8 ± 5.9 months).
We specified linear mixed-effects models with the
ADAS-cog as the dependent/outcome variable. Mixed
effects were used to account for the likely correlation of
repeated measurements within the same participant. We
used a linear specification for trajectory shape, and a lin-
ear term for time to specify the random effects of the
model. The lcmm package in R version 3.2.3 [10] was
used to fit the model. We tested the model for 1–10 la-
tent classes and the optimal number of latent classes
was assessed using the Bayesian Information Criterion
(BIC); the model which had the lowest BIC was selected.
At model convergence, a posterior probability of mem-
bership of the latent classes was calculated for each par-
ticipant, who was then assigned exclusively to the class
for which the highest probability was obtained. This ex-
clusive class assignment was used in order to allow sub-
sequent characterization of patient subgroups. Other a
priori specified patient-level variables, such as medica-
tion use and blood test analytes, were used to define
these subgroups’ distinguishing characteristics (a full list
of these variables is presented in Additional file 2).
Statistical description of latent classes
Categorical patient characteristics (gender, race, marital
status, originating trial/study and ApoE genotype) were
contrasted for the latent classes using chi-square tests.
Analyses of variance were applied to the continuous var-
iables (age at baseline, baseline ADAS-cog, number of
education years and the different blood analytes).
Tukey’s method for avoiding type I error was used for
post-hoc analysis. Blood analytes examined in this study
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include those measured in routine biochemistry and
haematology tests (Additional file 2). Association of
medication use with latent classes was explored with
tests of binomial proportions.
To test for differences in the slopes (rate of change) of
the ADAS-cog score between subgroups of patients, we
used a mixed-effects model implemented in R (using the
lme4 package [11]). The model included the group effect,
the visit (time) effect and group-by-visit interactions.
All analyses were computed using R version 3.2.3. Re-
sults are presented as the main effect with a 95% confi-
dence interval. A significance level of 5% was used for
main inferences.
Results
A total of 1160 AD participants assigned to placebo or un-
treated arms from nine clinical trials/studies, with at least
one assessment on the ADAS-cog (at baseline or there-
after), were included. These involved ADNI [12] and
ADCS studies evaluating the effects of simvastatin [13],
docosahexaenoic acid supplementation [14], oestrogen re-
placement therapy [15], B vitamin supplementation [16],
rofecoxib or naproxen [17], huperzine A [18], valproate
[19] and prednisone [20], selected for their inclusion of a
placebo-treated arm and the availability of evaluations for
an overlapping duration of follow-up. A total of 4856
observations (ADAS-cog scores) over a period of
18 months were included for our analysis. The number of
observations per participant ranged from 1 to 10, with a
mean ± SD of 4.2 ± 1.9 ADAS-cog scores per participant.
Our analysis of integrated data from these studies
identified three subgroups of AD patients displaying
unique trajectories of disease: 10.3% in Class 1, 76.5% in
Class 2 and 13.2% in Class 3 (with mean posterior prob-
abilities of 0.82, 0.93 and 0.79 respectively). All three
classes, on average, exhibited cognitive decline over
time. Participants within Class 2 and Class 3 exhibited
moderate or slower cognitive decline (with varying
starting points) whereas Class 1 demonstrated a steeper
decline (Fig. 1).
At baseline, no differences in gender, race, marital sta-
tus or ApoE genotype were evident between the three
classes of cognitive decline (Table 1). In addition, no dif-
ferences in the rate of decline in cognitive scores were
found between participants in placebo-treated arms and
those who were not treated at all (the two treatment
groups pooled in this dataset).
Participants in Class 1 were overall younger and had a
higher mean number of years of education (significantly in
comparison to Class 2, P < 0.001 and P < 0.05, respectively;
Fig. 2). Participants in Class 3 demonstrated the highest
baseline ADAS-cog scores (P < 0.001), lower levels of
monocyte counts and calcium levels (significantly in com-
parison to Class 2, P < 0.05) and the highest levels of
serum glucose (P < 0.05; Fig. 2). Interestingly, Class 2 dem-
onstrated the lowest baseline ADAS-cog scores and a
Fig. 1 Three classes of ADAS-cog trajectories (higher score is associated with lower cognitive function/greater decline) in participants from placebo or
no treatment arms of clinical trials/studies. a Disease progression trajectories estimated by our latent class mixed model, where an increase in ADAS-cog
scores (y axis) indicates worsening of cognitive function. b–d Individual participant trajectories for each of the three resulting classes (each line represents a
single participant). Bold lines represent a smoothing of the data; shaded areas represent the 0.95 confidence interval. ADAS-cog Alzheimer’s
Disease Assessment Scale—cognitive subscale
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significantly higher proportion of participants with a his-
tory of statin use (28.4% vs 19.3% in Class 1 and 22.2% in
Class 3, P < 0.05). No significant differences between the
resulting classes were found for the any of the other evalu-
ated medication groups.
Discussion
To advance a precision medicine approach to AD, this
study aimed to identify clinically relevant endopheno-
types of AD, characterized by patterns of disease pro-
gression and clinical characteristics, which may prove to
be biological endotypes.
We identified subgroups of patients based on a longi-
tudinal analysis of high-quality integrated AD clinical
trial data. We considered the possible existence of 1–10
subgroups/classes of disease progression. Using pre-
defined criteria, the best fit was identified for a three-
class model reflecting three subgroups of disease
progression and cognitive decline. Class 1 was character-
ized by rapid and steep progression of cognitive decline:
a mean decline > 10 points in the ADAS-cog. Class 3
was characterized by a greater cognitive deficit at base-
line which increased modestly over time, while Class 2
displayed a lower level of cognitive deficit which did not
reach the levels seen in Classes 1 and 3.
The three classes had differing clinical features. Class 1
patients tended to be younger and had more education,
while those in Class 3 had lower monocyte counts and
calcium levels, and higher levels of serum glucose. Age
and severity of cognitive impairment have been reported
previously as predictors of deterioration [5, 21, 22]. The
importance of these characteristics is further demon-
strated here, where younger age was found to be associ-
ated with a worse trajectory of progression (Class 1) and
where lower baseline cognitive impairment was associated
with slower decline (Class 2). Higher levels of education,
as seen in Class 1, have also been found previously to be
associated with risk for rapid cognitive decline [23]. There
was no significant difference in gender, race, marital status
and ApoE genotype across the three trajectory classes.
The most striking clinical features of the three classes
were their pattern of cognitive decline—the structure of
Table 1 Baseline characteristics
Entire cohort Class 1 Class 2 Class 3
Number of participants 1160 119 888 153
Duration of follow-up (months) 12.8 ± 5.9 13.6 ± 4.2 13.3 ± 5.7 9.1 ± 6.7
Age 75.6 ± 8.1 73.1 ± 8.9 76.1 ± 7.8 74.7 ± 8.6
Gender
Female 590 (50.9) 58 (48.7) 443 (49.9) 89 (58.2)
Male 472 (40.7) 50 (42.0) 367 (41.3) 55 (35.9)
Missing 98 (8.4) 11 (9.2) 78 (8.8) 9 (5.9)
Education 14.0 ± 3.2 14.8 ± 3.2 13.9 ± 3.3 14.0 ± 2.9
Race
Asian 8 (0.7) 1 (0.8) 6 (0.7) 1 (0.7)
African American 59 (5.1) 6 (5) 45 (5.1) 8 (5.2)
White 1007 (86.8) 103 (86.8) 771 (86.8) 133 (86.9)
Other 28 (2.4) 0 (0) 22 (2.5) 6 (3.9)
Missing 58 (5) 9 (7.6) 44 (5) 5 (3.3)
Marital status
Divorced 70 (6.0) 8 (6.7) 55 (6.2) 7 (4.6)
Married 800 (69.0) 90 (75.6) 603 (67.9) 107 (69.9)
Never married 26 (2.2) 3 (2.5) 22 (2.5) 1 (0.7)
Widowed 243 (20.9) 16 (13.4) 195 (22.0) 32 (20.9)
Missing 21 (1.8) 2 (1.7) 13 (1.5) 6 (3.9)
ApoE4 carriers (%)a 63.5 65.7 63.6 62.6
Statin users 311 (26.8) 23 (19.3) 254 (28.4) 34 (22.2)
Baseline ADAS-cog 23.6 ± 9.6 26.5 ± 6.9 20.4 ± 6.7 40.9 ± 6.3
Baseline characteristics of participants in the entire cohort and in each of the resulting latent classes (in the three-class model). Data presented as mean ± standard
deviation or n (%) unless stated otherwise
ADAS-cog Alzheimer’s Disease Assessment Scale—cognitive subscale, ApoE4 Apolipoprotein E, allele 4
aPercent of those participants with relevant information available
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interest learned from the data, as well as the proportions
of patient membership with each of the classes. The
Class 1 rapid decline group had similar prevalence to
the severely impaired slow progression phenotype Class
3, but most participants were in the Class 2 phenotype
of low baseline cognitive deficit and slow progression of
decline thereafter. These findings may have significant
impact on powering clinical trials based on predicted
magnitude of change over time and potential stratifica-
tion. It may be the case that future clinical trials may
want to consider focusing on recruitment of those pa-
tients who would be predicted to fall into Class 1 of
rapid decliners as these may increase chances of success.
However, the reliability of baseline characteristics in
predicating class membership needs to be assessed and
validated carefully, potentially in an independent cohort.
Furthermore, since Class 1 covers only 10.3% of trial
participants, recruiting only those patients would likely
encumber trials, as the majority of AD subjects would
be excluded. Additionally, to use these trajectories as a
prognostic tool, future work should aim to validate our
results in a cohort with a significant duration of follow-
up, preferably of several years.
The ApoE4 allele is one of the most significant risk
factors for sporadic AD [24]. Because the proportion of
ApoE4 carriers within each class of disease progression
did not significantly differ, ApoE4 genotype is unlikely to
drive disease trajectories in the same way that it stratifies
populations by the risk of developing AD, at least in
mild to moderate AD clinical trial subjects and based on
the cognitive measures tested in these. This observation
is in agreement with other studies showing that ApoE4
does not significantly influence the rate of cognitive
decline in AD [25, 26].
We have previously reported a subset of Alzheimer’s
patients on statin therapy demonstrating improved cog-
nitive function [27], supporting the existence of a re-
sponder subset of patients who would benefit from
treatment with statins. By taking a different approach,
these findings are further supported by analysis within
the current study, where a subgroup (Class 2: lower
ADAS-cog at baseline and slower decline) was also asso-
ciated with a higher use of statins. Of the different medi-
cation types examined in this study, statin use was the
only one to be statistically different between the result-
ing classes. However, it should be noted that this does
not necessarily mean that other medications do not have
potential therapeutic or preventative effects in AD. For
example, it would be very difficult to draw conclusions
regarding the effect of NSAIDs as these are not always
taken on a regular basis. Unlike statins, diabetes medica-
tions, antidepressants or oestrogens, where it is likely
Fig. 2 Baseline characteristics that are significantly different between the latent classes (subgroups of patients) identified from clinical trial/study data.
Grey lines depict significantly different class pairs (determined by post-hoc analysis). ADAS-cog Alzheimer’s Disease Assessment
Scale—cognitive subscale
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that patients prescribed these are taking them on a regu-
lar and continuous basis, reported use of NASIDs at
baseline might not reflect continuous use of these.
Furthermore, here we examined the association of use of
different medications with the different patient subgroups
and trajectories. This is by no means an in-depth examin-
ation of any potential therapeutic effect; it may be the case
that the association with statin use is confounded by other
factors such as prevalence of cardiovascular comorbidities,
differences in prescribing practices or better routine
medical care.
A potential limitation of this study stems from the
source and pooling of subjects from diverse clinical tri-
als. Firstly, participants recruited into clinical trials may
not accurately represent the more general AD patient
population; a participant’s reason for joining a trial may
differentiate them from the general population, introdu-
cing some bias. Secondly, by combining data from differ-
ent trials, participant variability may be increased since
selection criteria for each of these individual trials may
have been different. However, since our study utilized
data from participants within the placebo and no treat-
ment arms of trials, variability was not influenced by treat-
ment. Furthermore, by including subjects from multiple
trials, we are more likely to capture the spectrum of AD
patients who may enrol in future trials. Even with poten-
tial heterogeneity and variability across the years that
studies were conducted, and inclusion and exclusion cri-
teria based on the therapeutic intervention being tested,
clinically meaningful subgroups with unique trajectories
of disease progression were successfully detected.
This study has generated data-driven, plausible hy-
potheses about potential endotypes of AD, which could
be used to repurpose or seek new targets for treatment
or prevention. The unsupervised statistical learning
technique used here has also been applied to type 2 dia-
betes, identifying meaningful patterns of pre-disease and
BMI [28]. Similarly, model-based machine learning ap-
proaches have been used to discover important endo-
types of allergy and asthma [29]. The growing use of
unsupervised statistical and machine-learning methods,
applied to large-scale patient-level data, shows great
promise for better longitudinal characterization of AD.
This may in turn lead to better precision diagnostics and
more precise interventions. Future work should focus on
identifying molecular biomarkers that distinguish be-
tween the trajectories identified here. This will provide
more precisely defined endotypes which may be used to
better stratify patients as well as inform on biological
mechanisms driving disease progression.
Conclusion
We identified three clinical phenotypes of AD, with dis-
tinct trajectories of slow decline, severely impaired but
slow decline, or rapid decline. Further research is needed
to discover the biological mechanisms that may explain
these subgroups as endotypes. Additionally, this study
demonstrates how precision medicine approaches to AD
can be informed by learning from existing datasets such
as clinical trials. The findings presented here have the
potential to contribute to more effective targeting of tri-
als, medications and other interventions for the benefit
of Alzheimer’s patients, thus potentially impacting AD
patient management and care significantly.
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